The Technical Analyst
Pulmatrix Inc [PULM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Pulmatrix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.04% $1.990
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.27 mill |
| EPS: | -3.87 |
| P/E: | -0.510 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 3.65 mill |
| Avg Daily Volume: | 0.0157 mill |
| RATING 2024-04-19 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.510 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.510 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.864 - 2.12 ( +/- 6.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-01-26 | Siegert Michelle | Buy | 9 900 | Stock Option (Right to Buy) |
| 2023-01-26 | Wasilewski Margaret | Buy | 11 400 | Stock Option (Right to Buy) |
| 2023-01-26 | Raad Teofilo David | Buy | 34 900 | Stock Option (Right to Buy) |
| 2023-01-26 | Bazemore Todd | Buy | 1 700 | Stock Option (Right to Buy) |
| 2023-01-26 | Higgins Michael J | Buy | 2 436 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 13 676 591 | Sell: 104 308 |
Forecast:
16:00 - $1.990
Live Trading Signals (every 1 min)
Forecast
1: 14:46 - $2.00
Forecast 2: 15:36 - $1.967
Forecast 3: 16:00 - $1.990
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.990 (2.04% ) |
| Volume | 0.0120 mill |
| Avg. Vol. | 0.0157 mill |
| % of Avg. Vol | 76.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PULM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PULM
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Latest Press Releases
2024-03-28 09:05:00 - Press Release
Pulmatrix Announces Year-end And Q4 2023 Financial Results And Provides Corporate Update
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into q1 2026 3rd amendment to cipla partnership resulted in the wind down of the pur1900 phase 2b study and a significant reduction in expected cash burn for pulmatrix cipla to take sole responsibility for development of pur1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to pulmatrix bedford, mass. , march 28, 2024 /prnewswire/ -- pulmatrix, inc. ("pulmatrix" or the "company") (nasdaq: pulm), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation isperse™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.
2024-01-08 09:00:00 - Press Release
Pulmatrix Announces Stopping The Pur1900 Phase 2b Study Patient Enrollment And Closing The Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Pursuit Of Strategic Alternatives
Cipla to take sole responsibility for development of pur1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to pulmatrix pulmatrix to significantly reduce cash burn and focus on strategic alternatives that leverage the company's promising pipeline, isperse™ technology and approximately $19 million cash on hand as of 12/31/23 bedford, mass. , jan. 8, 2024 /prnewswire/ -- pulmatrix, inc. ("pulmatrix" or the "company") (nasdaq: pulm), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced that it has entered into a further amendment to its agreement with cipla for the development of pur1900 in the treatment of allergic bronchopulmonary aspergillosis (abpa).
2023-11-09 09:05:00 - Press Release
Pulmatrix Announces Third Quarter 2023 Financial Results And Provides Corporate Update
Patient enrollment for the phase 2b study of pur1900 is ongoing with four additional sites added during q3, totaling seventeen active sites to date in four countries; topline data anticipated in h2 2024 received "study may proceed" letter on an ind for a phase 2 study of pur3100 for acute migraine $21.3 million in cash and cash equivalents at the end of q3 2023 providing projected cash runway into q1 2025 bedford, mass. , nov. 9, 2023 /prnewswire/ -- pulmatrix, inc. (nasdaq: pulm), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation isperse™ technology, today announced third quarter financial results for 2023 and provided a corporate update on its development programs.
2023-09-19 09:05:00 - Press Release
Pulmatrix Announces Fda Acceptance Of Ind Application For Pur3100 To Treat Acute Migraine
Pulmatrix received a study may proceed letter for a phase 2 study to evaluate pur3100, an orally inhaled dry powder formulation of dihydroergotamine ("dhe") in the treatment of acute migraine bedford, mass. , sept. 19, 2023 /prnewswire/ -- pulmatrix, inc. ("pulmatrix" or the "company") (nasdaq: pulm), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the u.s. food and drug administration ("fda") has accepted the pur3100 investigational new drug ("ind") application and the company has received a study may proceed letter for a phase 2, multicenter, randomized, double-blind, placebo-controlled, single event study to evaluate the safety, tolerability, and efficacy of pur3100 (dihydroergotamine mesylate inhalation powder) in the acute treatment of migraine.
2023-08-23 09:05:00 - Press Release
Pulmatrix Announces Publication On Physiologically Based Pharmacokinetic Modelling Of Potential Drug-drug Interactions With Pur1900, Orally Inhaled Itraconazole
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when pur1900 is administered with medications contraindicated with oral itraconazole pulmatrix is currently enrolling patients in a phase 2 study of pur1900 in adults with abpa and asthma bedford, mass. , aug. 23, 2023 /prnewswire/ -- pulmatrix, inc. (nasdaq: pulm), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented isperse™ technology.
Latest News
2023-05-24 09:05:00 - PRNewsWire
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 - 8, 2023.
2023-01-23 09:05:00 - PRNewsWire
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the acceptance of an abstract for presentation at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, to be held February 24-27, 2023 in San Antonio, Texas.
2022-03-01 10:59:53 - InvestorPlace
Which U.S. Companies Are Cutting Ties With Russia? See Latest List.
U.S. companies are cutting ties with Russia due to the war with Ukraine and we're going over which ones traders need to know about. The post Which U.S. Companies Are Cutting Ties With Russia?
2022-03-01 08:04:07 - Pulse2
Pulmatrix (PULM) Stock: 1-For-20 Reverse Split Goes Into Effect
A 1-for-20 reverse split of Pulmatrix Inc (NASDAQ: PULM) stock has gone into effect. These are the details.
2021-11-10 20:36:08 - Zacks Investment Research
Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-10-06 10:30:42 - Zacks Investment Research
Bet on Rising P/E Investing With These Top 5 Stocks
2021-08-10 09:10:00 - PRNewsWire
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its second quarter 2021 financial results and provides a business update.
2021-05-12 06:31:24 - Pulse2
PULM Stock: Over 4% Increase Pre-Market Explanation
The stock price of Pulmatrix Inc (NASDAQ: PULM) increased by over 4% pre-market. This is why it happened.
2021-05-11 16:35:00 - PRNewsWire
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its first quarter 2021 financial results and provides a business update.
2021-04-15 09:15:00 - PRNewsWire
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it will host a key opinion leader (KOL) webinar on PUR3100, Pulmatrix's orally inhaled dihydroergotamine (DHE) therapy for the treatment of acute migraine, on Friday, April 23, 2021 at 10:00am Eastern Time.